AP1891A - HIV immunogenic compositions and methods. - Google Patents

HIV immunogenic compositions and methods.

Info

Publication number
AP1891A
AP1891A APAP/P/2001/002300A AP2001002300A AP1891A AP 1891 A AP1891 A AP 1891A AP 2001002300 A AP2001002300 A AP 2001002300A AP 1891 A AP1891 A AP 1891A
Authority
AP
ARIPO
Prior art keywords
mammal
immunogenic compositions
hiv
iss
adjuvant
Prior art date
Application number
APAP/P/2001/002300A
Other versions
AP2001002300A0 (en
Inventor
Ronald B Moss
Original Assignee
The Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Immune Response Corp filed Critical The Immune Response Corp
Publication of AP2001002300A0 publication Critical patent/AP2001002300A0/en
Application granted granted Critical
Publication of AP1891A publication Critical patent/AP1891A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides immunogenic compositions which enhance ?-chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing b-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. Also provided is a method of inhibiting aids, by enhancing ?-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.
APAP/P/2001/002300A 1999-05-06 2000-05-05 HIV immunogenic compositions and methods. AP1891A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13276299P 1999-05-06 1999-05-06
US15066799P 1999-08-25 1999-08-25
PCT/US2000/012495 WO2000067787A2 (en) 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods

Publications (2)

Publication Number Publication Date
AP2001002300A0 AP2001002300A0 (en) 2001-12-31
AP1891A true AP1891A (en) 2008-09-23

Family

ID=26830710

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002300A AP1891A (en) 1999-05-06 2000-05-05 HIV immunogenic compositions and methods.

Country Status (8)

Country Link
EP (1) EP1176978A2 (en)
AP (1) AP1891A (en)
AU (1) AU4992900A (en)
BR (1) BR0010323A (en)
CA (1) CA2372960C (en)
CR (1) CR6491A (en)
OA (1) OA11937A (en)
WO (1) WO2000067787A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ATE464907T1 (en) 1999-02-17 2010-05-15 Csl Ltd IMMUNOGENIC COMPLEXES AND METHODS RELATING THEM
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU5821000A (en) * 1999-06-29 2001-01-31 Smithkline Beecham Biologicals (Sa) Vaccine
DE60131430T2 (en) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services OLIGODE OXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE REACTION
AU2002231336B2 (en) 2000-12-27 2007-06-28 Surefire Medical, Inc. D/B/A Trisalus Life Sciences Immunomodulatory polynucleotides and methods of using the same
SG152045A1 (en) * 2001-01-26 2009-05-29 Immune Response Corp Inc Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
US8114418B2 (en) 2001-06-21 2012-02-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—IV
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
CN1604795B (en) 2001-08-17 2010-05-26 科勒制药股份公司 Combinatorial motif immunostimulatory oligopeptides with increased activity
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
JP2005532067A (en) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド Nucleic acid composition for stimulating immune response
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN1753687A (en) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Application of CPG oligonucleotide in the treatment of hepatitis C virus infection
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
ES2381309T3 (en) 2002-12-23 2012-05-25 Dynavax Technologies Corporation Sequence of immunostimulatory oligonucleotides and methods for using them
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN101291691A (en) * 2003-08-28 2008-10-22 免疫反应公司 Immunogenic HIV compositions and related methods
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
KR101251707B1 (en) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
EP3456316A1 (en) 2011-07-06 2019-03-20 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
CN103781470A (en) 2011-07-06 2014-05-07 诺华股份有限公司 Oil-in-water emulsions that contain nucleic acids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Vaccine, GB, Butterworth Scientific, Guildford, Vol. 16, No. 7, 1 *
Vaccine, Vol. 18, No. 11-12, 01/2000 *

Also Published As

Publication number Publication date
EP1176978A2 (en) 2002-02-06
WO2000067787A3 (en) 2001-04-26
AP2001002300A0 (en) 2001-12-31
CR6491A (en) 2005-05-31
OA11937A (en) 2006-04-12
AU4992900A (en) 2000-11-21
CA2372960C (en) 2006-03-28
WO2000067787A2 (en) 2000-11-16
BR0010323A (en) 2002-01-08
CA2372960A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
AP1891A (en) HIV immunogenic compositions and methods.
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
MXPA01011047A (en) Neisseria genomic sequences and methods of their use.
EP1373301A4 (en) Reducing the immunogenicity of fusion proteins
TW200621806A (en) Vaccine
WO2001053463A3 (en) COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES
MXPA01003557A (en) Neisseria genomic sequences and methods of their use.
MXPA02005639A (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions.
IL155283A0 (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
AU2001262345A1 (en) Antigenic composition comprising a polycationic peptide and inosine and cytosine
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
WO2004007679A3 (en) Dendritic cell pontentiation
ZA200500073B (en) Iscom preparation and use thereof.
MXPA04001224A (en) Agents for enhancing the immune response.
DE59913046D1 (en) INFLUENZA VIRUS VACCINE COMPOSITION
NZ525752A (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
NZ333500A (en) Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
BR9712556A (en) Plasmid, pharmaceutical composition, and, process of immunizing an individual against an antigen
WO2005021726A3 (en) Immunogenic hiv compositions and related methods
TW200502245A (en) Vaccine
AU6078399A (en) Ligand presenting assembly (lpa), method of preparation and uses thereof
MXPA02003328A (en) Vaccine.